A Phase 2 interventional study of Deucravacitinib in Central Centrifugal Cicatricial Alopecia and Frontal Fibrosing Alopecia, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Icahn School of Medicine at Mount Sinai · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 217 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.
Among the 217 studies in Alopecia with a site in United States, this one is the 152nd largest by planned enrollment of the 204 interventional ones that give a count, is one of 15 that started in 2026, is one of 48 in phase 2, reaches primary completion later than 58 of the 62 other live ones, and was the 206th registered.
512 studies on the registry are indexed under Alopecia; 127 are open to participants now.
Browse Alopecia studies →43 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:
Pelage Pharmaceuticals, Inc. · Sites in United States
Ages 18–65 · Women only
Pelage Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 18–55 · Men only
Johns Hopkins University · Sites in United States
Ages 18–80
University of Miami · Sites in United States
Ages 18+
K. Kay Durairaj, MD, FACS, A Medical Corporation · Sites in United States
Ages 35–55 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
217 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 58 · Phase 3 17 · Phase 4 9
First in 2000; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 40 across the 204 interventional studies, 204 across the 12 observational. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
124 of 217 have an industry lead sponsor. The 10 most frequent:
Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 175 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.
Icahn School of Medicine at Mount Sinai has 5 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
28 of the studies in Alopecia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972264Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Males With AGA | 2026-12 |
| NCT07146022Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | 2027-06 |
| NCT04207931Wake Forest University Health SciencesTreatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study | 2026-11 |
| NCT05416333Wake Forest University Health SciencesAzelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) | 2026-11 |
| NCT07588243CynosureLutronicA Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth | 2026-12 |
Add all 28 to your calendar (.ics) → With an account.
Among the 217 studies in Alopecia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 weeks. Approximately 20 participants will be enrolled: 10 Central Centrifugal Cicatricial Alopecia (CCCA) and 10 Frontal Fibrosing Alopecia (FFA). The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS). At the Baseline/Day 0 visit, participants will initiate treatment with deucravacitinib. All participants will receive deucravacitinib 12mg once-daily for 48 weeks. The treatment period will conclude at week 48.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contains individuals diagnosed with Central Centrifugal Cicatricial Alopecia.
Drug: Deucravacitinib
Contains individuals diagnosed with Frontal Fibrosing Alopecia.
Drug: Deucravacitinib
6mg twice-daily oral treatment for 48 weeks.
Changes in IFNγ in CA scalp
Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24
Time frame: Baseline to Week 24
Changes in CCL5 in CA scalp
Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24
Time frame: Baseline to Week 24
Changes in CXCL9 in CA scalp
Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24
Time frame: Baseline to Week 24
Changes in CXCL10 in CA scalp
Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24
Time frame: Baseline to Week 24
Changes in TGFB1/2 in CA scalp
Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24
Time frame: Baseline to Week 24
Changes in vimentin in CA scalp
Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24
Time frame: Baseline to Week 24
Changes in fibronectin CA scalp
Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24
Time frame: Baseline to Week 24
Changes in CTGF in CA scalp
Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24
Time frame: Baseline to Week 24
Changes in IFNγ in CA scalp
Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24
Time frame: Week 24 to Week 48
Changes in CCL5 in CA scalp
Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24
Time frame: Week 24 to Week 48
Changes in CXCL9 in CA scalp
Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24
Time frame: Week 24 to Week 48
Changes in CXCL10 in CA scalp
Changes in TH1 markers in Cicatricial Alopecias on the scalp from Baseline to Week 24
Time frame: Week 24 to Week 48
Changes in TGFB1/2 in CA scalp
Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24
Time frame: Week 24 to Week 48
Changes in vimentin in CA scalp
Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24
Time frame: Week 24 to Week 48
Changes in fibronectin CA scalp
Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24
Time frame: Week 24 to Week 48
Changes in CTGF in CA scalp
Changes in biomarkers of fibrosis in Cicatricial Alopecias on the scalp from Baseline to Week 24
Time frame: Week 24 to Week 48
Change in The Central Hair Loss Grade (CHLG)
Change in CHLG from baseline at week 24 and week 48. The Central Hair Loss Grade is a clinical measure of severity that uses a 6 points scale (0 no central scalp hair loss, 1 - minimal central scalp hair loss, 2 - clinically evident central scalp hair loss, 3-5 advanced central scalp hair loss).
Time frame: Baseline to Week 24; Baseline to Week 48
Change in Frontal Fibrosing Alopecia Severity Index (FFASI)
Change in FFASI from baseline at week 24 and week 48. The Frontal Fibrosis Alopecia Severity Index utilizes clinical images of the entire hairline divided into 4 sections. Score from 1-5, with higher score indicating more severity.
Time frame: Baseline to Week 24; Baseline to Week 48
Changes in mRNA Levels of CCL5 gene expression in skin biopsies
Evaluation of how the two skin conditions (CCCA and FFA) present themselves at the microscopic level. The skin samples will be obtained via biopsies. Changes in mRNA Levels of CCL5 gene expression in skin biopsies quantified by normalized Ct values obtained by quantitative real-time PCR assay, measured at baseline and week 24. The unit of the outcome is called Ct value and it represents the number of amplification cycles to reach a level of fluorescence in the experiment. The Ct value is directly associated to the level of expression of a gene
Time frame: baseline and week 24
Change in Alopecia Areata Quality of Life Index (AA-QLI)
Change in Alopecia Areata Quality of Life Index (AA-QLI) in week 24 and week 48. The scores range from 0 - 30 with 0 representing no impact to quality of life and 30 representing extremely large impact.
Time frame: Week 24 and Week 48
Change in Peak Pruritus Numerical Rating Scale (PP-NRS)
Change in Peak Pruritus Numerical Rating Scale (PP-NRS) at week 24 and week 48. The score ranges from 0 - 10 with 0 representing no itch and 10 representing worse possible itch.
Time frame: Week 24 and Week 48
Change in hair count per cm2
Change in number of hairs present in a 1 cm2 area between Baseline to Week 24 and Baseline to Week 48
Time frame: Baseline to Week 24; Baseline to Week 48
Change in sum of hair width per cm2
Change in total hair diameter in a 2 cm2 area between Baseline to Week 24 and Baseline to Week 48
Time frame: Baseline to Week 24; Baseline to Week 48
Change in terminal:vellus ratio
Change in the ratio of thick pigmented long hair to fine-barely visible hairs between Baseline to Week 24 and Baseline to Week 48
Time frame: Baseline to Week 24; Baseline to Week 48
Change in average hairs per follicular unit
Change in hair density in a 1 cm2 area between Baseline to Week 24 and Baseline to Week 48
Time frame: Baseline to Week 24; Baseline to Week 48
Change in average hair width
Change in average width of each individual hair between Baseline to Week 24 and Baseline to Week 48
Time frame: Baseline to Week 24; Baseline to Week 48
Change in follicular units per cm2
Change in hair density in a 1 cm2 area between Baseline to Week 24 and Baseline to Week 48
Time frame: Baseline to Week 24; Baseline to Week 48
Change in inter-follicular mean distance
Change in average gap between hairs using a diagnotic tool called the HairMetrix diagnostic tool that can accurately measure the interfollicular distance between baseline to Week 24 and baseline to Week 48
Time frame: Baseline to Week 24; Baseline to Week 48
Plan to share: No — Results will be analyzed and published as aggregate data.
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Jun 2028, 25 months after the start.
Of 42 phase 2 interventional studies under Alopecia, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 25 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib
Icahn School of Medicine at Mount Sinai →